An Phase I Trial of a CAR T-cell Infusion C-CAR031 in Participants With GPC3+ Advanced/Metastatic Squamous Cell Lung Cancer

This single-arm, open-label, multicenter, Phase I study will evaluate the safety, tolerability, anti-tumor activity, pharmacokinetics (PK)/pharmacodynamics (PD), biomarker, and immunogenicity of C-CAR031 in adult participants with GPC3+ advanced/metastatic squamous cell lung cancer, who are not amenable to curative therapy and have progressed or are intolerant to no more than 3 lines of prior systemic treatment including immune checkpoint inhibitors (CPIs) and platinum-based doublet chemotherapy, concurrently or sequentially.

NCT Number	NCT07444281
Lead Sponsor	Shanghai AbelZeta Ltd.
Conditions	Squamous Cell Lung Cancer
Enrollment	24 participants
Start Date	2024-12-25
Primary Completion	2027-04-30 (estimated)
Study Completion	2028-01-30 (estimated)
Updated on ClinicalTrials.gov	2026-03-03